Preventing Lung Cancer: The 14-Protein Blood Test and Canakinumab

New Research Leads To Lung Cancer Prevention

Lung cancer is the third most common cancer in the U.S. and the leading cause of cancer-related deaths globally. This disease often grows silently, and symptoms don’t appear until advanced stages. Lung cancer starts in your airways, damages the lungs, and then can spread to other organs. Once it has spread outside the lungs, it is generally not curable.

Preventing Lung Cancer

More than 80 researchers across 4 continents have worked to identify specific proteins that predict lung cancer approximately 5 years before diagnosis. 

• The 14-Protein Blood Signature: A unique pattern of 14 key proteins in the blood can accurately identify lung cancer risk. Rather than detecting a tumor, these proteins reflect a pre-disease state of lung inflammation generally caused by environmental factors such as air pollution or cigarette smoke.

• Early Detection and Prevention: Scientists linked these specific protein concentrations to early biological changes in the lungs. Locating these proteins could allow doctors to discover high-risk individuals and start preventative therapies long before cancer develops.

• Protein Analysis: This protein signature suggests that it does not come from the tumor itself, but reflects an inflamed lung environment that preceded lung cancer.

More research and clinical trials are needed to formulate a patient test based on these recently discovered proteins. This new and vital information was recently published, and experts are excited about this promising starting point. This is a major step toward precision cancer medicine.

Inflammation And Prevention

This signature group of 14 proteins was also found in patients who later developed idiopathic pulmonary fibrosis or chronic obstructive pulmonary disease (COPD). This supports the idea that this group of proteins may signal the presence of lung inflammation.

Lung inflammation and lung cancer are deeply linked:

• Chronic Inflammation: Long-term inflammation from irritants like cigarette smoke, asbestos, and frequent infections fills lung tissue with immune cells and stress chemicals. These chemicals cause the release of free radicals that can damage the DNA. This causes a risk of cells mutating and growing uncontrollably, which will cause a tumor to grow quickly.

• Tumors Can Create Their Own Inflammation: Once cancer develops in the lungs, it continues to grow and spread. Tumors also use the body’s immune system to survive. They release signals that gather white blood cells into the lungs. Instead of killing the cancer, these white blood cells help it to grow.

• Inflammation From Treatment: It is common for inflammation to happen because of the treatment to fight the cancer. Radiation or some immunotherapies can overstimulate the immune system, which causes it to attack healthy lung tissue.

A New Medication For Prevention

Inflammation is a target that doctors could treat before cancer develops. To explore this idea, researchers looked back at data from 4,650 patients in a randomized trial for the medication, canakinumab. This drug targets the same inflammatory pathways that are associated with the 14 protein signature. This trial showed that patients who took canakinumab had a reduced incidence of lung cancer.

Canakinumab (Ilaris) is an immunosuppressive antibody that blocks interleukin-1 beta (IL-1β), a key protein that drives chronic inflammation. 

How it is associated with lung cancer:

• Reducing Inflammation: Chronic inflammation promotes the growth and spread of precancerous cells. By neutralizing IL-1β, canakinumab suppresses this inflammatory environment, which slows tumor growth and prevents precancerous cells from spreading.

• Can-Prevent-Lung Trial: This is a Phase II trial testing whether canakinumab can prevent lung cancer. Thus far, most patients are showing a decrease in their tumor growth. And lesions in the treatment group have a significantly smaller number of cells.

• Combination Treatment: Extensive research has been done to see if canakinumab can be used in combination with standard immunotherapies (like pembrolizumab) or surgery to kill cancer cells and prevent a relapse.
  

The Effects Of Canakinumab

A previous trial that followed patients taking canakinumab (and were monitored for 3-5 years) found that the effects of this medication were dose dependent. In the patients taking the highest dose (300mg), there was a 67% reduction in lung cancer incidence. Mortality rates were also much lower in the canakinumab group versus the placebo group.

Ongoing trials are exploring how canakinumab can shrink high-risk pulmonary nodules. Early data suggest that it is well-tolerated as a preventive measure. However, when it was combined with standard cytotoxic chemotherapy (such as docetaxel), canakinumab did not significantly improve overall survival for non-small cell lung cancer (NSCLC). Canakinumab is not yet FDA-approved.

Because this drug works by suppressing the immune system’s inflammatory pathways, it has several side effects:

• Serious Infections: The most critical risk of this medication is a higher risk of fatal infections and sepsis. 

• Respiratory Issues: Common cold symptoms, upper respiratory infections, sore throat, runny nose, and cough.

• Tuberculosis: This drug increases the risk of developing latent or active tuberculosis.

• Blood Counts: Decreased neutrophils and platelets are a common side effect, which can be problematic when combined with other cancer therapies.

• Gastrointestinal Problems: Nausea, vomiting, diarrhea, and stomach pain.

• General Pain And Fatigue: Back, muscle, and joint pain as well as general body aches.

• Metabolic Changes: Weight gain and increased levels of fats in the blood.

• Allergic Reactions: Rare, but life-threatening allergic reactions are possible, including hives, swelling of the face and throat, or difficulty breathing.

Conclusion

The discovery of a 14-protein blood signature can identify lung cancer risk years before a diagnosis. This marks a significant advancement in cancer prevention research. By focusing on chronic inflammation as an early disease symptom, doctors may be able to identify high-risk individuals and intervene before cancer even develops. 

Preventive treatments such as canakinumab represent an important step toward personalized medicine that can provide early intervention. As research continues, the ability to predict and prevent lung cancer offers great hope to millions of people worldwide.